← All trials
NCT03869060
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 4, 2019
- Primary completion
- Oct 31, 2019
- Completion date
- Feb 29, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 9
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- State University of New York, SyracuseLead sponsor
- Janssen Pharmaceutica NVCollaborator
- United States ArmyCollaborator
- State University of New York, SyracuseOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.